XML 75 R63.htm IDEA: XBRL DOCUMENT v3.24.3
Segments of Business - Reportable operating segment (Details)
$ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2024
USD ($)
segment
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
segment
Sep. 30, 2023
USD ($)
Mar. 31, 2024
USD ($)
Segment revenues          
Total revenues $ 93,651 $ 77,215 $ 172,934 $ 151,698  
Segment operating profit (loss)          
Total operating profit (loss) 578 951 1,607 2,051  
Subtotal 861 1,141 2,123 2,483  
Corporate income (expenses), net (249) (164) (352) (368)  
Interest expense (78) (61) (153) (108)  
Income before income taxes 534 916 $ 1,618 2,007  
Number of reportable segments | segment     4    
Accounts receivable, credit loss expense (reversal)     $ (169) 243  
Proceeds from legal settlements 63        
Pre-tax credits related to LIFO accounting     (4) 87  
Restructuring, impairment, and related charges, net 234 28 244 80  
Income (loss) from equity method investments     (43)    
Restructuring charges 149 10 148 12  
Canadian businesses held for sale     638 0  
Gains (losses) associated with equity investments (15) 0 95 0  
Canadian retail disposal group | Held-for-sale          
Segment operating profit (loss)          
Canadian businesses held for sale 643   643    
Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization          
Segment operating profit (loss)          
Restructuring, impairment, and related charges, net $ 227 3 227 39  
Rx Savings Solutions, LLC          
Segment operating profit (loss)          
Fair value adjustment gain   48   76  
United States          
Segment operating profit (loss)          
Number of reportable segments | segment 3        
Corporate          
Segment operating profit (loss)          
Restructuring, impairment, and related charges, net $ 23 6 24 46  
Restructuring charges 4 0 3 1  
Gains (losses) associated with equity investments     95    
Corporate | Canadian retail disposal group          
Segment operating profit (loss)          
Other comprehensive loss 50   50    
Corporate | National Prescription Opioid Litigation          
Segment operating profit (loss)          
Pre-tax expenses related to estimated litigation liability     51    
U.S. Pharmaceutical          
Segment revenues          
Total revenues 85,726 69,766 157,441 136,926  
Segment operating profit (loss)          
Total operating profit (loss) 1,075 593 1,856 1,420  
Accounts receivable, credit loss expense (reversal) 203 210 203 210 $ 725
Proceeds from legal settlements 63 79 153 197  
U.S. Pharmaceutical | Operating Segments          
Segment operating profit (loss)          
Pre-tax credits related to LIFO accounting (2) 55 (4) 87  
Restructuring, impairment, and related charges, net 64 9 65 11  
Restructuring charges 1 8 1 9  
U.S. Pharmaceutical | Operating Segments | Restructuring Initiatives QTD          
Segment operating profit (loss)          
Restructuring, impairment, and related charges, net 64   64    
U.S. Pharmaceutical | Operating Segments | National Prescription Opioid Litigation          
Segment operating profit (loss)          
Pre-tax expenses related to estimated litigation liability     57    
Prescription Technology Solutions          
Segment revenues          
Total revenues 1,265 1,140 2,506 2,384  
Segment operating profit (loss)          
Total operating profit (loss) 205 238 408 469  
Prescription Technology Solutions | Operating Segments          
Segment operating profit (loss)          
Restructuring, impairment, and related charges, net 1 3 5 5  
Restructuring charges 0 0 0 0  
Medical-Surgical Solutions          
Segment revenues          
Total revenues 2,948 2,834 5,584 5,445  
Segment operating profit (loss)          
Total operating profit (loss) 89 244 277 471  
Medical-Surgical Solutions | Operating Segments          
Segment operating profit (loss)          
Restructuring, impairment, and related charges, net 147 4 150 6  
Restructuring charges 144 0 144 0  
International          
Segment revenues          
Total revenues 3,709 3,475 7,400 6,943  
Segment operating profit (loss)          
Total operating profit (loss) (508) 66 (418) 123  
International | Canadian retail disposal group | Held-for-sale          
Segment operating profit (loss)          
Canadian businesses held for sale 593   593    
International | Operating Segments          
Segment operating profit (loss)          
Restructuring, impairment, and related charges, net (1) 6 0 12  
Restructuring charges 0 2 0 2  
Corporate          
Segment revenues          
Total revenues $ 3 $ 0 $ 3 $ 0  
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | U.S. Pharmaceutical          
Segment operating profit (loss)          
Revenue derived from services, percentage (approximately or less than) 1.00%        
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | Prescription Technology Solutions          
Segment operating profit (loss)          
Revenue derived from services, percentage (approximately or less than) 40.00%        
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | Medical-Surgical Solutions          
Segment operating profit (loss)          
Revenue derived from services, percentage (approximately or less than) 1.00%        
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | International          
Segment operating profit (loss)          
Revenue derived from services, percentage (approximately or less than) 1.00%